Navigating the immunosuppressive abyss: current hurdles and innovative breakthroughs in neoadjuvant immunotherapy for osteosarcoma
Guanghao Chen, Minjie Hu, Zhongkun Li, Kunpeng Yang, Bao Chen, Tianhao Xu · 2026
Read Navigating the immunosuppressive abyss: current hurdles and innovative breakthroughs in neoadjuvant immunotherapy for osteosarcoma by Guanghao Chen, Minjie Hu, Zhongkun Li, Kunpeng Yang, Bao Chen, Tianhao Xu (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13617527.txt.
Description
Guanghao Chen, Minjie Hu, Zhongkun Li, Kunpeng Yang, Bao Chen, and Tianhao Xu review the hard road to using immunotherapy before surgery for osteosarcoma, the commonest bone cancer of the young. Their 2026 review notes that chemotherapy before surgery once lifted survival, then progress stalled. Treating while the tumor and its draining lymph nodes remain intact should, in theory, prime T cells at the source.
The authors are careful: an intact tumor is not automatically a vaccine, and swollen lymphocyte counts do not prove tumor-specific attack. Benefit likely hinges on antigen quality, presentation machinery, available reactive clones, and how reversible the local suppression is. Low mutation counts, a myeloid-heavy neighborhood, and no selection biomarkers all block translation. They propose matching strategies to barriers, judged by pathology, spatial profiling, and molecular clearance together.
Catalog record
| CREATOR | Guanghao Chen, Minjie Hu, Zhongkun Li, Kunpeng Yang, Bao Chen, Tianhao Xu |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 106 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |